Telix Pharmaceuticals Ltd (TLX)
NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations
- Price
- $11.27
- Day
- -5.69%
Close 2026-09-23.
The company
A. History and Development of the Company Our legal name is Telix Pharmaceuticals Limited. Our company was incorporated under the laws of Australia in January 2017. In November 2017, we completed an initial public offering of our ordinary shares and the listing of our ordinary shares on the ASX. Since November 13, 2024, we have been dual listed with our ADSs listed on the Nasdaq Global Select Market, with each ADS representing one of our ordinary shares. JP Morgan Chase Bank, N.A., acts as depositary for the ADSs. Our corporate headquarters and registered offices are located at 55 Flemington Road, North Melbourne, Victoria, 3051, Australia. Our reception telephone number is +61 3 9093 3855. Our agent for service of process in the U.S. is Telix Pharmaceuticals (US) Inc., located at 11700 Exit 5 Pkwy, Suite 200, Fishers, Indiana 46037. Our website address is www.telixpharma.com. B. Business Overview Introduction We are a global, commercial-stage biopharmaceutical company, focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. We are committed to the principles of precision oncology. By this we mean developing both therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as ‘theranostics’. Overview Our portfolio includes both therapeutic and diagnostic radiopharmaceutical product candidates designed for use throughout the continuum of the patient journey, from diagnosis and staging to treatment and ongoing care.
From Item 1: A. History and Development of the Company · B. Business Overview · Introduction · Overview.
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- FMR LLC — $6.1M
- LAZARD ASSET MANAGEMENT LLC — $3.28M
- PORTLAND INVESTMENT COUNSEL INC. — $3.07M
- Private Advisor Group, LLC — $2.27M
- MARSHALL WACE, LLP — $2.14M
- Integrated Wealth Concepts LLC — $1.9M
- MORGAN STANLEY — $1.89M
- Hennion & Walsh Asset Management, Inc. — $1.73M
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- Smith Darren Charlton (Group Chief Financial Officer) bought 2,071 shares at $9.66 on 2026-09-07
- Behrenbruch Christian (MD & Group CEO) bought 33,435 shares at $14.87 on 2026-04-29
- Behrenbruch Christian (MD & Group CEO) bought 34,500 shares at $14.48 on 2026-04-28
Recent filings
- 6-K — 2026-09-21
- 4 — 2026-09-14
- 6-K — 2026-09-14
- 6-K — 2026-09-02
- 6-K — 2026-09-01
- 6-K — 2026-08-20
- 6-K — 2026-07-21
- 6-K — 2026-07-02
- 6-K — 2026-05-21
- 3 — 2026-05-18